YumanityLogo.jpg
Yumanity Therapeutics to Present at Upcoming Virtual Investor Conferences
May 27, 2021 07:00 ET | Yumanity Therapeutics Inc
BOSTON, May 27, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics’ R&D Day Reviews Near-Term Value Drivers and Pipeline-Generating Discovery Engine
May 17, 2021 16:05 ET | Yumanity Therapeutics Inc
Clinical efforts expanding to three programs consisting of: the on-going Phase 1b portion of the YTX-7739 Phase 1 program in Parkinson’s disease patients with top line results expected in mid-2021...
YumanityLogo.jpg
Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments
May 13, 2021 07:00 ET | Yumanity Therapeutics Inc
Demonstrated lead program YMTX-7739 inhibits novel target in healthy volunteers at levels consistent with improved motor function in an animal model of Parkinson’s disease Initiated dosing in Phase...
YumanityLogo.jpg
Yumanity Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference
May 12, 2021 08:00 ET | Yumanity Therapeutics Inc
BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics to Host Virtual R&D Day on Monday, May 17, 2021
May 04, 2021 08:00 ET | Yumanity Therapeutics Inc
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative...
YumanityLogo.jpg
Yumanity Therapeutics to Present at the 2021 B. Riley Securities’ Neuroscience Conference
April 28, 2021 20:07 ET | Yumanity Therapeutics Inc
BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics’ YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a Multiple Ascending Dose Study in Healthy Volunteers
April 22, 2021 07:00 ET | Yumanity Therapeutics Inc
BOSTON, April 22, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Appoints Neuroscience Drug Development Veteran, Ajay Verma, M.D., Ph.D., Executive Vice President, Head of Research & Development
April 13, 2021 08:00 ET | Yumanity Therapeutics Inc
BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for...
YumanityLogo.jpg
Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a Glioblastoma Multiforme (GBM) Mouse Model
April 06, 2021 08:00 ET | Yumanity Therapeutics Inc
YTX-7739 demonstrates efficacy, including increased median overall survival, both as a single agent and in combination with temozolomide, the standard-of-care for GBM Shared therapeutic target with...
YumanityLogo.jpg
Yumanity Therapeutics Reports Full Year 2020 Financial Results and Recent Corporate Developments
March 31, 2021 08:48 ET | Yumanity Therapeutics Inc
Closed $33.6 million PIPE in conjunction with the completion of reverse merger with Proteostasis Therapeutics; commenced trading on the Nasdaq Capital Market under the ticker symbol “YMTX” ...